Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLONG-003: enlonstobart combined with chemoradiotherapy for locally advanced cervical cancer
ChiCTR2400091264Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of PBI-1308 in Cervical Cancer (CC) (2 cohorts), sponsored by Union Hospital. Primary endpoint: 2-year progression-free survival rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400091264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091264.